https://www.merck.com/news/merck-and-pfizer-announce-that-investigational-sglt-2-inhibitor-ertugliflozin-met-primary-endpoint-in-two-phase-3-studies/
Merck and Pfizer Announce That Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint...
May 11, 2026 - Ertugliflozin as Add-on to Metformin or in Initial Co-administration with Sitagliptin Showed Significant A1C Reductions in Adults with Type 2 Diabetes...
sglt 2 inhibitor